BR112017008799A2 - composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal - Google Patents
composições de apilimod e métodos de uso das mesmas no tratamento de câncer renalInfo
- Publication number
- BR112017008799A2 BR112017008799A2 BR112017008799A BR112017008799A BR112017008799A2 BR 112017008799 A2 BR112017008799 A2 BR 112017008799A2 BR 112017008799 A BR112017008799 A BR 112017008799A BR 112017008799 A BR112017008799 A BR 112017008799A BR 112017008799 A2 BR112017008799 A2 BR 112017008799A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- kidney cancer
- treating kidney
- apilimod
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
a presente invenção refere-se a métodos para o tratamento de câncer renal com apilimod e composições e métodos relacionados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462077127P | 2014-11-07 | 2014-11-07 | |
PCT/US2015/059512 WO2016073877A1 (en) | 2014-11-07 | 2015-11-06 | Apilimod for use in the treatment of renal cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017008799A2 true BR112017008799A2 (pt) | 2017-12-19 |
Family
ID=54548302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017008799A BR112017008799A2 (pt) | 2014-11-07 | 2015-11-06 | composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal |
Country Status (16)
Country | Link |
---|---|
US (3) | US10206910B2 (pt) |
EP (2) | EP3215158B1 (pt) |
JP (1) | JP6705828B2 (pt) |
KR (1) | KR20170098812A (pt) |
CN (1) | CN107249638B (pt) |
AU (1) | AU2015342869A1 (pt) |
BR (1) | BR112017008799A2 (pt) |
CA (1) | CA2966359A1 (pt) |
ES (1) | ES2741399T3 (pt) |
HU (1) | HUE044557T2 (pt) |
IL (1) | IL251905B (pt) |
MX (1) | MX2017006015A (pt) |
PL (1) | PL3215158T3 (pt) |
PT (1) | PT3215158T (pt) |
RU (1) | RU2727802C2 (pt) |
WO (1) | WO2016073877A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2937655C (en) | 2014-01-24 | 2022-06-28 | Lam Therapeutics, Inc. | Apilimod compositions for cancer treatment |
EP3215158B1 (en) | 2014-11-07 | 2019-05-08 | AI Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
US20190209576A1 (en) * | 2014-11-07 | 2019-07-11 | AI Therapeutics, Inc. | Apilimod for use in the treatment of colorectal cancer |
JP2019502707A (ja) * | 2016-01-21 | 2019-01-31 | ラム・セラピューティクス,インコーポレーテッド | 癌をアピリモドで処置するためのバイオマーカー |
CN109952113A (zh) * | 2016-08-25 | 2019-06-28 | 人工智能治疗公司 | 包含pikfyve抑制剂的组合物和与rank信号传导的抑制相关的方法 |
CN110167559A (zh) * | 2016-10-12 | 2019-08-23 | 人工智能治疗公司 | 阿匹莫德组合物和将其用于治疗阿尔茨海默病中的方法 |
CN110662544A (zh) | 2017-03-24 | 2020-01-07 | 纳诺森公司 | 具有有用的药学应用的稠合***并嘧啶化合物 |
US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
MX2020008680A (es) * | 2018-02-21 | 2020-09-25 | Ai Therapeutics Inc | Terapia de combinacion con apilimod y agentes glutamatergicos. |
AU2020393842A1 (en) | 2019-11-25 | 2022-06-16 | The Regents Of The University Of California | Long-acting VEGF inhibitors for intraocular neovascularization |
CN114306370A (zh) * | 2021-12-31 | 2022-04-12 | 北京悦康科创医药科技股份有限公司 | 反义寡核苷酸在制备治疗肾癌药物中的应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
PT1921169E (pt) | 1993-11-12 | 2012-05-23 | Phri Properties Inc | Sondas de hibridação para detecção de ácidos nucleicos, troncos universais, métodos e estojos |
US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
US20050255118A1 (en) | 2004-02-06 | 2005-11-17 | Nancy Wehner | Methods and composition for treating tumors and metastatic disease |
EP1737845A4 (en) | 2004-04-13 | 2010-07-21 | Synta Pharmaceuticals Corp | DISPLAY HEMMER OF IL-12 PRODUCTION |
JP2008512490A (ja) | 2004-09-08 | 2008-04-24 | チェルシー・セラピューティクス,インコーポレイテッド | 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤 |
TW200630363A (en) | 2004-11-10 | 2006-09-01 | Synta Pharmaceuticals Corp | Process for preparing trisubstituted pyrimidine compounds |
WO2006124662A1 (en) | 2005-05-13 | 2006-11-23 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
WO2006128129A2 (en) * | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
PT1951724E (pt) | 2005-11-17 | 2011-08-02 | Osi Pharm Inc | Inibidores mtor fundidos bicíclicos |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
JP5156644B2 (ja) | 2006-01-25 | 2013-03-06 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | 不飽和mTOR阻害剤 |
EP2038252B1 (en) | 2006-07-12 | 2016-11-02 | University of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
AU2008213808B2 (en) | 2007-02-06 | 2011-11-10 | Novartis Ag | PI 3-kinase inhibitors and methods of their use |
RU2438664C2 (ru) | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
DE102007036076A1 (de) * | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
JP5258331B2 (ja) | 2008-03-03 | 2013-08-07 | ロート製薬株式会社 | 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物 |
WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
US9180105B2 (en) | 2010-03-08 | 2015-11-10 | Sloan-Kettering Institute For Cancer Research | CDC7 kinase inhibitors and uses thereof |
CN102905707A (zh) * | 2010-03-29 | 2013-01-30 | 味之素株式会社 | 含有苯基丙氨酸衍生物的医药制剂 |
US8402515B2 (en) | 2010-05-06 | 2013-03-19 | Jonathan Weizman | Apparatus and method for establishing a peer-to-peer communication session with a client device |
WO2011146727A1 (en) | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of treating interstitial cystitis |
US8709419B2 (en) * | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
EP2640712B1 (en) | 2010-11-19 | 2018-07-11 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | 2-piperazin-1-yl-4h-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections |
WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
EP2903644A4 (en) | 2012-10-05 | 2016-03-09 | Cerulean Pharma Inc | TREATMENT OF CANCER |
US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
CA2937655C (en) * | 2014-01-24 | 2022-06-28 | Lam Therapeutics, Inc. | Apilimod compositions for cancer treatment |
EP3215158B1 (en) | 2014-11-07 | 2019-05-08 | AI Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
US20190209576A1 (en) | 2014-11-07 | 2019-07-11 | AI Therapeutics, Inc. | Apilimod for use in the treatment of colorectal cancer |
KR101761573B1 (ko) | 2014-12-29 | 2017-07-26 | 주식회사 인트론바이오테크놀로지 | 신규한 장출혈성 대장균 박테리오파지 Esc-CHP-1 및 이의 장출혈성 대장균 증식 억제 용도 |
US20180015098A1 (en) | 2015-02-03 | 2018-01-18 | Lam Therapeutics, Inc. | Apilimod compositions and methods for using same |
US20180078561A1 (en) | 2015-03-31 | 2018-03-22 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ai治療公司 | 使用阿吡莫德治療癌症之方法 |
AU2019299234A1 (en) | 2018-07-05 | 2021-01-14 | Mayo Foundation For Medical Education And Research | PIKfyve inhibitors |
US20210077500A1 (en) | 2019-09-12 | 2021-03-18 | Al Therapeutics, Inc. | Pikfyve inhibitors for cancer therapy |
-
2015
- 2015-11-06 EP EP15795318.3A patent/EP3215158B1/en active Active
- 2015-11-06 US US15/524,844 patent/US10206910B2/en active Active
- 2015-11-06 AU AU2015342869A patent/AU2015342869A1/en not_active Abandoned
- 2015-11-06 PT PT15795318T patent/PT3215158T/pt unknown
- 2015-11-06 CA CA2966359A patent/CA2966359A1/en not_active Abandoned
- 2015-11-06 CN CN201580072608.8A patent/CN107249638B/zh not_active Expired - Fee Related
- 2015-11-06 PL PL15795318T patent/PL3215158T3/pl unknown
- 2015-11-06 HU HUE15795318 patent/HUE044557T2/hu unknown
- 2015-11-06 MX MX2017006015A patent/MX2017006015A/es active IP Right Grant
- 2015-11-06 RU RU2017119065A patent/RU2727802C2/ru active
- 2015-11-06 KR KR1020177015388A patent/KR20170098812A/ko not_active Application Discontinuation
- 2015-11-06 JP JP2017543329A patent/JP6705828B2/ja not_active Expired - Fee Related
- 2015-11-06 WO PCT/US2015/059512 patent/WO2016073877A1/en active Application Filing
- 2015-11-06 BR BR112017008799A patent/BR112017008799A2/pt not_active Application Discontinuation
- 2015-11-06 ES ES15795318T patent/ES2741399T3/es active Active
- 2015-11-06 EP EP19171060.7A patent/EP3581184B1/en active Active
-
2017
- 2017-04-24 IL IL251905A patent/IL251905B/en active IP Right Grant
-
2018
- 2018-12-19 US US16/226,175 patent/US20190201385A1/en not_active Abandoned
-
2019
- 2019-11-26 US US16/695,814 patent/US11166944B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2017119065A (ru) | 2018-12-07 |
PL3215158T3 (pl) | 2019-11-29 |
PT3215158T (pt) | 2019-08-23 |
CA2966359A1 (en) | 2016-05-12 |
IL251905B (en) | 2021-03-25 |
MX2017006015A (es) | 2017-11-17 |
RU2017119065A3 (pt) | 2019-06-05 |
IL251905A0 (en) | 2017-06-29 |
EP3581184A1 (en) | 2019-12-18 |
WO2016073877A1 (en) | 2016-05-12 |
US20200297706A1 (en) | 2020-09-24 |
CN107249638B (zh) | 2021-05-14 |
EP3215158A1 (en) | 2017-09-13 |
JP2017535601A (ja) | 2017-11-30 |
US20170333408A1 (en) | 2017-11-23 |
EP3215158B1 (en) | 2019-05-08 |
ES2741399T3 (es) | 2020-02-10 |
EP3581184B1 (en) | 2021-02-24 |
JP6705828B2 (ja) | 2020-06-03 |
RU2727802C2 (ru) | 2020-07-24 |
HUE044557T2 (hu) | 2019-11-28 |
US11166944B2 (en) | 2021-11-09 |
AU2015342869A1 (en) | 2017-06-15 |
KR20170098812A (ko) | 2017-08-30 |
CN107249638A (zh) | 2017-10-13 |
US20190201385A1 (en) | 2019-07-04 |
US10206910B2 (en) | 2019-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017008799A2 (pt) | composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal | |
CL2018002782A1 (es) | Apósito modificado | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
BR112019006160A2 (pt) | composições e métodos para o tratamento das condições oftálmicas | |
BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
BR112017006664A2 (pt) | terapias de combinação | |
BR112017011771A2 (pt) | métodos e composições para o tratamento de câncer | |
DK3119808T3 (da) | Antistofsammensætninger til tumorbehandling | |
EA201790380A1 (ru) | Ингибиторы mk2 и их применения | |
BR112018000776A2 (pt) | métodos para tratamento de câncer usando apilimod | |
BR112015028115A2 (pt) | métodos e composições para o tratamento de câncer | |
DK3380086T3 (da) | Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer | |
BR112017009265A2 (pt) | apilimode para uso no tratamento do câncer colorretal | |
BR112018012313A2 (pt) | composições que compreendem 15-hepe e métodos para uso das mesmas | |
DK3456330T3 (da) | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer | |
CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
PH12016501422A1 (en) | Functionalised benzopyran compounds and use thereof | |
DK3253208T3 (da) | Kombinationsterapier til anvendelse i behandlingen af brystcancer | |
DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft | |
BR112017000303A2 (pt) | métodos para o tratamento de hipotensão | |
EP3148526A4 (en) | Use of eribulin in the treatment of cancer | |
PH12016501838A1 (en) | Compounds and their methods of use | |
EA201591709A1 (ru) | 5-бром-индирубины | |
MX2016005473A (es) | Metodos y composiciones para mejorar la funcion renal. | |
BR112017011685A2 (pt) | composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B25D | Requested change of name of applicant approved |
Owner name: AI THERAPEUTICS, INC. (US) |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |